BLS Pharmaceuticals sees FY27 adjusted EBITDA margin 23%-26%
BLS Pharmaceuticals expects FY27 adjusted EBITDA margin in the 23%-26% range.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.